Kahraman, S. Et Al. 2025. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study. Clinical Breast Cancer .

Kahraman, S., Erul, E., GÜMÜŞAY, Ö., GÜVEN, D. C., AKSOY, S., BAŞARAN, G., ... Seyyar, M.(2025). Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study. Clinical Breast Cancer .

Kahraman, Seda Et Al. "Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study," Clinical Breast Cancer , 2025

Kahraman, Seda Et Al. "Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study." Clinical Breast Cancer , 2025

Kahraman, S. Et Al. (2025) . "Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study." Clinical Breast Cancer .

@article{article, author={Seda Kahraman Et Al. }, title={Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study}, journal={Clinical Breast Cancer}, year=2025}